Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Autor:	Hoffman RM; Department of Medicine, University of California, Los Angeles, California, USA., Brummel S; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Ziemba L; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Chinula L; UNC Chapel Hill Department of Obstetrics & Gynecology, UNC Project Malawi, Lilongwe, Malawi., McCarthy K; FHI 360, Durham, North Carolina, USA., Fairlie L; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa., Jean-Philippe P; Maternal Adolescent Pediatric Research Branch, Division of AIDS, National Institutes of Health, Rockville, Maryland, USA., Chakhtoura N; National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA., Johnston B; Frontier Science Foundation, Amherst, New York, USA., Krotje C; Frontier Science Foundation, Amherst, New York, USA., Nematadzira TG; University of Zimbabwe-UCSF Collaborative Research Programme, Chitungwiza, Zimbabwe., Nakayiwa F; MUJHU Care Limited, Kampala, Uganda., Ndyanabangi V; Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda., Hanley S; Department of Family Medicine, Centre for the AIDS Programme of Research and University of KwaZulu-Natal, Durban, South Africa., Theron G; Stellenbosch University, Stellenbosch, South Africa., Violari A; Perinatal HIV Research Unit, University of the Witwatersrand, Soweto, South Africa., João E; Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil., Correa MD  Jr; Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Hofer CB; Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Navanukroh O; Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand., Aurpibul L; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand., Nevrekar N; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University, Pune, India., Zash R; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Shapiro R; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Stringer JSA; Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Currier JS; Department of Medicine, University of California, Los Angeles, California, USA., Sax P; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lockman S; Department of Medicine, Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1617-1628.
DOI:	10.1093/cid/ciae001
Abstrakt:	Background: We evaluated associations between antepartum weight change and adverse pregnancy outcomes and between antiretroviral therapy (ART) regimens and week 50 postpartum body mass index in IMPAACT 2010. Methods: Women with human immunodeficiency virus (HIV)-1 in 9 countries were randomized 1:1:1 at 14-28 weeks' gestational age (GA) to start dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) versus DTG + FTC/tenofovir disoproxil fumarate (TDF) versus efavirenz (EFV)/FTC/TDF. Insufficient antepartum weight gain was defined using Institute of Medicine guidelines. Cox-proportional hazards regression models were used to evaluate the association between antepartum weight change and adverse pregnancy outcomes: stillbirth (≥20 weeks' GA), preterm delivery (<37 weeks' GA), small size for GA (<10th percentile), and a composite of these endpoints. Results: A total of 643 participants were randomized: 217 to the DTG + FTC/TAF, 215 to the DTG + FTC/TDF, and 211 to the EFV/FTC/TDF arm. Baseline medians were as follows: GA, 21.9 weeks; HIV RNA, 903 copies/mL; and CD4 cell count, 466/μL. Insufficient weight gain was least frequent with DTG + FTC/TAF (15.0%) versus DTG + FTC/TDF (23.6%) and EFV/FTC/TDF (30.4%). Women in the DTG + FTC/TAF arm had the lowest rate of composite adverse pregnancy outcome. Low antepartum weight gain was associated with higher hazard of composite adverse pregnancy outcome (hazard ratio, 1.44 [95% confidence interval, 1.04-2.00]) and small size for GA (1.48 [.99-2.22]). More women in the DTG + FTC/TAF arm had a body mass index ≥25 (calculated as weight in kilograms divided by height in meters squared) at 50 weeks postpartum (54.7%) versus the DTG + FTC/TDF (45.2%) and EFV/FTC/TDF (34.2%) arms. Conclusions: Antepartum weight gain on DTG regimens was protective against adverse pregnancy outcomes typically associated with insufficient weight gain, supportive of guidelines recommending DTG-based ART for women starting ART during pregnancy. Interventions to mitigate postpartum weight gain are needed. Competing Interests: Potential conflicts of interest. R. M. H. is an Elsevier ClinicalKey editorial board member. R. M. H. also reports honoraria for lectures on this topic from the Los Angeles County Division of HIV and STI Programs and the UCLA CARE Center’s continuing medical education seminars. S. B. and L. Z. reports support for the present work from the NIH Division of AIDS/Eunice Kennedy Shriver National Institute of Child Health and Human Development and ViiV/GSK, paid to their institution. L. F. reports grants or contracts for the current study through NIH/IMPAACT. S. H. reports grants or contracts from UKZN Developing Research Innovation, Localisation and Leadership in South Africa (DRILL), the Fogarty International Center, the NIH Common Fund, Office of Strategic Coordination, Office of the Director, Office of AIDS Research, the NIH Office of the Director, the National Institute of Mental Health, NIH (award D43TW010131, paid to their institution, from January 2018 to July 2023), and the SA National Research Foundation (Thuthuka funding grant, paid to their institution, from January 2019 to December 2021). R. Z. reports receipt of study medication from ViiV healthcare for a federally funded research study (as principal investigator); ViiV is donating long-acting cabotegravir for an implementation study of preexposure prophylaxis in Botswana, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. J. S. C. is a scientific advisor for Merck, participating on its advisory board, and reports royalties or licenses from UpToDate. P. S. reports grants or contracts from Gilead and ViiV; consulting fees from Gilead, Janssen, Merck, and ViiV; and participation on a data safety monitoring board or advisory board for Merck. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu